Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 134

1.

Efficacy of highly active antiretroviral therapy in HIV-1 infected children.

van Rossum AM, Fraaij PL, de Groot R.

Lancet Infect Dis. 2002 Feb;2(2):93-102. Review.

PMID:
11901656
2.

Lopinavir/ritonavir: a review of its use in the management of HIV infection.

Cvetkovic RS, Goa KL.

Drugs. 2003;63(8):769-802. Review.

PMID:
12662125
3.

Association of serum lipid levels with HIV serostatus, specific antiretroviral agents, and treatment regimens.

Anastos K, Lu D, Shi Q, Tien PC, Kaplan RC, Hessol NA, Cole S, Vigen C, Cohen M, Young M, Justman J.

J Acquir Immune Defic Syndr. 2007 May 1;45(1):34-42.

PMID:
17460470
4.

Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.

Verweel G, van Rossum AM, Hartwig NG, Wolfs TF, Scherpbier HJ, de Groot R.

Pediatrics. 2002 Feb;109(2):E25.

PMID:
11826235
5.

Virological and immunological responses to HAART in asymptomatic therapy-naive HIV-1-infected subjects according to CD4 cell count.

Rizzardi GP, Tambussi G, Bart PA, Chapuis AG, Lazzarin A, Pantaleo G.

AIDS. 2000 Oct 20;14(15):2257-63.

PMID:
11089613
6.

Simplification of protease inhibitor-containing regimens with efavirenz, nevirapine or abacavir: safety and efficacy outcomes.

Chiesa E, Bini T, Adorni F, Capetti A, Rizzardini G, Faggion I, Mussini C, Sollima S, Melzi S, Bongiovanni M, Tordato F, Cicconi P, Castelnuovo B, Rusconi S, d'Arminio Monforte A.

Antivir Ther. 2003 Feb;8(1):27-35.

PMID:
12713061
7.

Different kinetics of immunologic recovery using nelfinavir or lopinavir/ritonavir-based regimens in children with perinatal HIV-1 infection.

De Luca M, Miccinesi G, Chiappini E, Zappa M, Galli L, De Martino M.

Int J Immunopathol Pharmacol. 2005 Oct-Dec;18(4):729-35.

PMID:
16388722
8.

Long-term survival and immuno-virological response of African HIV-1-infected children to highly active antiretroviral therapy regimens.

Rouet F, Fassinou P, Inwoley A, Anaky MF, Kouakoussui A, Rouzioux C, Blanche S, Msellati P; ANRS 1244/1278 Programme Enfants Yopougon..

AIDS. 2006 Nov 28;20(18):2315-9.

PMID:
17117017
9.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503
10.

Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naive patients: a cohort study.

Matthews GV, Sabin CA, Mandalia S, Lampe F, Phillips AN, Nelson MR, Bower M, Johnson MA, Gazzard BG.

AIDS. 2002 Jan 4;16(1):53-61.

PMID:
11741163
11.

Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.

[No authors listed]

Prescrire Int. 2004 Aug;13(72):144-50.

PMID:
15532140
12.

Antiretroviral chemotherapy.

Saag MS, Schooley RT.

Curr Clin Top Infect Dis. 1998;18:154-79. Review. No abstract available.

PMID:
9779354
13.

Comparative biological and clinical outcomes after a switch from a virologically unsuccessful first protease inhibitor-containing antiretroviral combination to a 3-drug regimen containing efavirenz, nevirapine, or abacavir.

Abgrall S, Yeni PG, Bouchaud O, Costagliola D; Clinical Epidemiology Group of the French Hospital Database on HIV..

Clin Infect Dis. 2007 Jan 1;44(1):120-7.

PMID:
17143827
14.

Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the First Pediatric Switch Study.

McComsey G, Bhumbra N, Ma JF, Rathore M, Alvarez A; First Pediatric Switch Study..

Pediatrics. 2003 Mar;111(3):e275-81.

PMID:
12612284
15.

Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients.

Fätkenheuer G, Theisen A, Rockstroh J, Grabow T, Wicke C, Becker K, Wieland U, Pfister H, Reiser M, Hegener P, Franzen C, Schwenk A, Salzberger B.

AIDS. 1997 Nov 15;11(14):F113-6.

PMID:
9386799
16.

Efficacy of highly active antiretroviral therapy in HIV-infected children participating in Thailand's National Access to Antiretroviral Program.

Puthanakit T, Oberdorfer A, Akarathum N, Kanjanavanit S, Wannarit P, Sirisanthana T, Sirisanthana V.

Clin Infect Dis. 2005 Jul 1;41(1):100-7.

PMID:
15937769
17.

Clinical outcome and predictive factors of failure of highly active antiretroviral therapy in antiretroviral-experienced patients in advanced stages of HIV-1 infection.

d'Arminio Monforte A, Testa L, Adorni F, Chiesa E, Bini T, Moscatelli GC, Abeli C, Rusconi S, Sollima S, Balotta C, Musicco M, Galli M, Moroni M.

AIDS. 1998 Sep 10;12(13):1631-7.

PMID:
9764782
18.

Switch from a first virologically effective protease inhibitor-containing regimen to a regimen containing efavirenz, nevirapine or abacavir.

Abgrall S, Yeni PG, Bouchaud O, Costagliola D; Clinical Epidemiology Group from the French Hospital Database on HIV..

AIDS. 2006 Oct 24;20(16):2099-106.

PMID:
17053356
19.

Improvement in dyslipidaemia after switching stavudine to tenofovir and replacing protease inhibitors with efavirenz in HIV-infected children.

Viganò A, Aldrovandi GM, Giacomet V, Merlo M, Martelli L, Beretta S, Luraschi P, Rombolà G, Mora S.

Antivir Ther. 2005;10(8):917-24.

PMID:
16430197
20.

Supplemental Content

Support Center